From Garbage To Gucci

[Pennybuster]

$AVXL .40








Company website: http://www.anavex.com/



Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA
1-844-689-3939

CIK: 0001314052

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutics, referred to as “ANAVEX PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity. The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually. Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Management: http://www.anavex.com/about-us/leadership/

Pipeline: http://www.anavex.com/pipeline/

Patent Info: http://www.anavex.com/?s=patents

Clinical Trials: https://clinicaltrials.gov/ct2/results?term=Anavex+Life+Sciences&Search=Search

Recent News: http://finance.yahoo.com/q?s=avxl&ql=1
Company News Releases: http://www.anavex.com/2015/?post_type=news

Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=anavex&owner=exclude&action=getcompany

Share Structure: See SEC filings

Investor Relations: [e-mail]